Innoviva (INVA) Non-Current Deferred Tax Liability (2022 - 2026)

Innoviva's (INVA) quarterly Non-Current Deferred Tax Liability came in at $72.8 million in Q1 2026, up 129.08% on a QoQ basis from $31.8 million in Q4 2025.

Innoviva (INVA) Non-Current Deferred Tax Liability (2022 - 2026) Analysis & Trends

Innoviva (INVA) has 5 years of Non-Current Deferred Tax Liability data on file, last reported at $72.8 million in Q1 2026.

  • Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $72.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.8 million (changed N/A YoY) and the FY2025 annual result came in at $31.8 million, changed N/A from the prior year.
  • Non-Current Deferred Tax Liability advanced to $72.8 million in Q1 2026, from $31.8 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $72.8 million in Q1 2026 to a low of $563000.0 in Q4 2023.
  • A 5-year average of $20.0 million and a median of $5.6 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
  • Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability plunged 90.24% — and 2024, when it retreated 29.4%.
  • Tracing INVA's Non-Current Deferred Tax Liability over 5 years: stood at $5.8 million in 2022, then sank by 90.24% to $563000.0 in 2023, then jumped by 576.2% to $3.8 million in 2024, then soared by 735.12% to $31.8 million in 2025, then soared by 129.08% to $72.8 million in 2026.
  • The last three Non-Current Deferred Tax Liability figures came in at $72.8 million (Q1 2026), $31.8 million (Q4 2025), and $3.8 million (Q1 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Innoviva 1.54 Bn 968.79 Mn 90.62 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 36.74 Mn
Jun 30, 2026 36.74 Mn
Mar 31, 2026 72.83 Mn
Mar 31, 2026 72.83 Mn
Dec 31, 2025 31.79 Mn
Dec 31, 2025 31.79 Mn
Mar 31, 2024 3.81 Mn
Mar 31, 2024 3.81 Mn
Dec 31, 2023 563,000.00
Dec 31, 2023 563,000.00
Mar 31, 2023 5.39 Mn
Mar 31, 2023 5.39 Mn
Dec 31, 2022 5.77 Mn
Dec 31, 2022 5.77 Mn